Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - pregabalinum inn - hart hylki - 100 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - pregabalinum inn - hart hylki - 150 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - pregabalinum inn - hart hylki - 25 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - pregabalinum inn - hart hylki - 50 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - pregabalinum inn - hart hylki - 75 mg

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - pregabalinum inn - hart hylki - 300 mg

Європейський Союз - ісландська - EMA (European Medicines Agency)

bial - portela ca, s.a. - eslikarbazepín asetat - flogaveiki - antiepileptics, - exalief er ætlað til viðbótarmeðferðar hjá fullorðnum með flogaveiki með eða án aukakvilla.

Європейський Союз - ісландська - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

ge healthcare as - iodixanolum inn - stungulyf, lausn - 270 mg j/ml

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

ge healthcare as - iodixanolum inn - stungulyf, lausn - 320 mg j/ml